suspected covid-19; suspected covid-19; this is a spontaneous report received from a contactable reporter(s) (consumer or other non hcp) from the ra and product quality group. a female patient received bnt162b2 (comirnaty), administration date 07feb2022 (lot number: fn1664) as dose 3 (booster), single, (batch/lot number: unknown) as dose 2, single and (batch/lot number: unknown) as dose 1, single for covid-19 immunisation. the patient's relevant medical history and concomitant medications were not reported. the following information was reported: drug ineffective (medically significant), suspected covid-19 (medically significant) all with onset 12feb2022, outcome "unknown" and all described as "suspected covid-19". the patient underwent the following laboratory tests and procedures: sars-cov-2 test: no - negative covid-19 test. patient has not tested positive for covid-19 since having the vaccine. patient is not enrolled in clinical trial. the report did not relate to possible inflammation of the heart (myocarditis or pericarditis). no follow-up attempts are possible; information about lot/batch number cannot be obtained. no further information is expected

test name: covid-19 virus test; result unstructured data: test result:no - negative covid-19 test

na

na